Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.025
-0.175 (-7.95%)
Oct 10, 2025, 2:44 PM EDT - Market open

Relmada Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202011 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2011 - 2019
Selling, General & Admin
33.637.7248.8947.9335.0824.87
Upgrade
Research & Development
36.9246.1854.81113.3290.6235.97
Upgrade
Total Operating Expenses
70.5283.89103.7161.25125.760.84
Upgrade
Operating Income
70.5283.89103.7161.25125.760.84
Upgrade
Interest Income
2.273.535.152.661.21.4
Upgrade
Other Non-Operating Income (Expense)
0.440.38-0.241.55-1.25-0.02
Upgrade
Total Non-Operating Income (Expense)
2.723.914.914.21-0.051.38
Upgrade
Pretax Income
73.2487.8108.61165.45125.6662.22
Upgrade
Net Income
-67.81-79.98-98.79-157.04-125.75-59.46
Upgrade
Net Income to Common
-67.81-79.98-98.79-157.04-125.75-59.46
Upgrade
Shares Outstanding (Basic)
313030301816
Upgrade
Shares Outstanding (Diluted)
313030301816
Upgrade
Shares Change (YoY)
2.86%0.21%1.59%68.80%12.56%68.75%
Upgrade
EPS (Basic)
-2.22-2.65-3.28-5.30-7.16-3.81
Upgrade
EPS (Diluted)
-2.22-2.65-3.28-5.30-7.16-3.81
Upgrade
Free Cash Flow
-49.92-51.76-51.66-103.8-91.87-27.81
Upgrade
Free Cash Flow Per Share
-1.61-1.72-1.72-3.50-5.23-1.78
Upgrade
EBITDA
70.5283.89103.7161.25125.760.84
Upgrade
EBIT
70.5283.89103.7161.25125.760.84
Upgrade
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q